Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S277000
Reexamination Certificate
active
07863296
ABSTRACT:
Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-insomnia agent. Disclosed herein are also methods of treating insomnia using the disclosed pharmaceutical compositions.
REFERENCES:
patent: 3983234 (1976-09-01), Sayers
patent: 4138492 (1979-02-01), Noverola et al.
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4332804 (1982-06-01), Clark
patent: 4353900 (1982-10-01), Clark
patent: 4353901 (1982-10-01), Clark
patent: 4367232 (1983-01-01), Boix-Igleasias et al.
patent: 4401665 (1983-08-01), Sheinaus et al.
patent: 4853394 (1989-08-01), King et al.
patent: 4908369 (1990-03-01), Schechter et al.
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5214044 (1993-05-01), Cooper et al.
patent: 5214055 (1993-05-01), Peglion et al.
patent: 5216165 (1993-06-01), Mobilio et al.
patent: 5461066 (1995-10-01), Gericke et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5689488 (1997-11-01), Yamaguchi
patent: 5707798 (1998-01-01), Brann
patent: 5795894 (1998-08-01), Shue et al.
patent: 5869488 (1999-02-01), Shue et al.
patent: 5874445 (1999-02-01), Carr et al.
patent: 5877173 (1999-03-01), Olney et al.
patent: 5912132 (1999-06-01), Brann
patent: 5952324 (1999-09-01), Barbachyn et al.
patent: 5955281 (1999-09-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6479480 (2002-11-01), Moyes et al.
patent: 6486153 (2002-11-01), Castro Pineiro et al.
patent: 6617339 (2003-09-01), Gravestock
patent: 6756393 (2004-06-01), Andersson et al.
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6911452 (2005-06-01), Schlienger
patent: 7022698 (2006-04-01), Hamied et al.
patent: 7041667 (2006-05-01), Armour et al.
patent: 7115634 (2006-10-01), Thurieau et al.
patent: 7253186 (2007-08-01), Andersson et al.
patent: 7601740 (2009-10-01), Weiner et al.
patent: 2002/0004513 (2002-01-01), Andersson et al.
patent: 2002/0035145 (2002-03-01), Tsai et al.
patent: 2002/0156068 (2002-10-01), Behan et al.
patent: 2002/0165225 (2002-11-01), Hamied et al.
patent: 2003/0092700 (2003-05-01), Czollner et al.
patent: 2003/0220316 (2003-11-01), Andersson et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0106600 (2004-06-01), Andersson et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0014757 (2005-01-01), Andersson et al.
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0244862 (2005-11-01), Brann
patent: 2005/0256108 (2005-11-01), Schlienger
patent: 2006/0094758 (2006-05-01), Andersson et al.
patent: 2006/0106063 (2006-05-01), Thygesen et al.
patent: 2006/0111399 (2006-05-01), Thygesen et al.
patent: 2006/0194778 (2006-08-01), Andersson et al.
patent: 2006/0194834 (2006-08-01), Andersson et al.
patent: 2006/0199794 (2006-09-01), Schlienger
patent: 2006/0199818 (2006-09-01), Andersson et al.
patent: 2006/0199842 (2006-09-01), Weiner et al.
patent: 2006/0205710 (2006-09-01), Schlienger et al.
patent: 2006/0205722 (2006-09-01), Andersson et al.
patent: 2006/0205780 (2006-09-01), Thygesen et al.
patent: 2006/0205781 (2006-09-01), Thygesen et al.
patent: 2006/0264465 (2006-11-01), Weiner et al.
patent: 2006/0264466 (2006-11-01), Weiner et al.
patent: 2006/0286610 (2006-12-01), Brann
patent: 2006/0292606 (2006-12-01), Brann
patent: 984843 (1976-03-01), None
patent: 0 005 318 (1979-11-01), None
patent: 0056144 (1982-07-01), None
patent: 0 061 333 (1982-09-01), None
patent: 0 379 441 (1990-07-01), None
patent: 0 548 015 (1993-06-01), None
patent: 0 260 070 (1993-08-01), None
patent: 0 625 507 (1994-11-01), None
patent: 1656938 (2006-05-01), None
patent: 2802206 (2001-06-01), None
patent: 157325 (1998-03-01), None
patent: 51052176 (1976-05-01), None
patent: 5208517 (1977-05-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 97/08166 (1997-03-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/17646 (1998-04-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/87839 (2001-11-01), None
patent: WO 02/24649 (2002-03-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO-2002-076464 (2002-10-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/086400 (2003-10-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/009549 (2004-01-01), None
patent: WO-2004-039322 (2004-05-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064753 (2004-08-01), None
patent: WO 2004/072034 (2004-08-01), None
patent: WO-2005-042502 (2005-05-01), None
patent: WO-2005-053796 (2005-06-01), None
patent: WO 2005/063254 (2005-07-01), None
patent: WO 2005/112927 (2005-12-01), None
patent: WO-2005-115361 (2005-12-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/037043 (2006-04-01), None
patent: WO 2006/104826 (2006-10-01), None
Avemaria, F. et al., “Synthesis of aryl azides via post-cleavage modification of polymer-bound triazenes,” Synlett 7:1163-1166 (2004).
Barnes and Sharp, “A review of central 5-HT receptors and their function,” Neuropharmacology 38:1083-1152 (1999) (Abstract).
Barr and Manning, “Agonist-independent Activation of Gzby the 5-Hydroxytryptamine1AReceptor Co-expressed in Spodoptera frugiperda Cells,” J. Biol. Chem. 272:32979-32987 (1997).
Brane, “Identification of ligands by selective amplification of cells transfected with receptors and marker enzymes,” Chem Abstr. 128:111548 (1998).
Cerione, R.A. et al., “The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system,” Biochemistry 23:4519-4525 (1984) (Abstract).
Gershon et al., “5-Hydroxytryptamine and enteric neurones,” Chapter 11, pp. 247-272 from The Peripheral Actions of 5-Hydroxytryptamine (1989).
Glennon, R.A., “Serotonin receptors: clinical implications,” Neurosci. Biobehavioral Rev. 14:35-47 (1990).
Julius, D. et al., “The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors,” PNAS USA 87:928-932 (1990).
Meltzer, H.Y., “The Role of Serotonin in Antipsychotic Drug Action,” Neuropsychopharmacology 21:106S-115S (1999).
Moulignier, A. “Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications,” Rev. Neurol. 150:3-15 (1994) (Abstract).
Nagabina, N. et al., “Applied Technique of 1,3-Dipolar Cycloaddition to Synthesis of New Fluoroquinolones,” Russian J. Organic Chem., Consultants Bureau, US, pp. 1548-1555 (1997).
Saltzman, A.G. et al., “Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes,” Biochem. Biophys. Res. Comm. 181:1469-1478 (1991) (Abstract).
Saxena et al., “Cardiovascular Effects of Serotonin Agonists and Antagonists,” J. Cardiovascular Pharmacol. 15(Supp.7):S17-S34 (1990).
PCT/US06/076317 WO Search Report dated Jul. 20, 2006.
International Search Report and Written Opinion for PCT/US2005/017808 filed May 20, 2005, mailed Sep. 29, 2005, 13 pgs.
R. A. Bond et al., “Physiological effects of inverse agonists in transgenic mice with myocardlal overexpression of the β2—adrenoceptor”, Nature vol. 374, pp. 272-276, 1995.
D. M. Weiner, “5-Hydroxytryptamine2AReceptor Inverse Agonists as Antipsychotics”, J. Pharmaco
Brann Mark R.
Davis Robert E.
Frost-Jensen, legal representative Anna-Maria
Nash Norman
Weiner David M.
Acadia Pharmaceuticals Inc.
Javanmard Sahar
Jones Day
Padmanabhan Sreeni
LandOfFree
Selective serotonin receptor inverse agonists as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective serotonin receptor inverse agonists as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective serotonin receptor inverse agonists as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720991